Search Results

You are looking at 1 - 10 of 37 items for :

  • Refine by Access: Open Access content only x
Clear All
Open access

Louis W C Chow, Satoshi Morita, Christopher Y C Chow, Wai-Kuen Ng, and Masakazu Toi

relapse or breast cancer death risks. Ki67 proliferation index has been implicated as a surrogate marker of response for neoadjuvant hormonal therapy. A score of 2.7 or less was regarded as complete cell cycle arrest ( Ma et al. 2015 ). The

Open access

Anastasia Alataki and Mitch Dowsett

neoadjuvant setting, clinical response rates range from 50 to 70% of patients ( Colleoni & Montagna 2012 ). Almost all patients with advanced or metastatic ER+ breast cancer will relapse if treated with endocrine therapy alone during the first few years of

Open access

Julia Hoefer, Johann Kern, Philipp Ofer, Iris E Eder, Georg Schäfer, Dimo Dietrich, Glen Kristiansen, Stephan Geley, Johannes Rainer, Eberhard Gunsilius, Helmut Klocker, Zoran Culig, and Martin Puhr

Pearson's method. Differences in relapse-free survival, defined as biochemical recurrence, were assessed using the Kaplan–Meier plots and log-rank test. Differences were considered statistically significant when P was <0.05. Results SOCS2 expression

Open access

Catherine Zabkiewicz, Jeyna Resaul, Rachel Hargest, Wen Guo Jiang, and Lin Ye

breast cancers ( Cancer Research UK 2017 ). Even for those treated at an early stage, there is still a significant risk of relapse, often several years later. This is particularly true of oestrogen receptor-positive breast cancers, which are at a

Open access

Kristina Warton, Kate L Mahon, and Goli Samimi

following surgery and none of these four subjects experienced relapse. Conversely, of the remaining 12 who did have detectable ctDNA, all but one experienced relapse ( Diehl et al . 2008 ). The above study was based on mutations and used a highly

Open access

Per Eystein Lønning and Hans Petter Eikesdal

preventing recurrence. Among 9856 patients allocated to monotherapy with either tamoxifen or an aromatase inhibitor, following a mean duration of follow-up of 5.8 years, aromatase inhibitor monotherapy decreased relapse rate from 12.6% (for tamoxifen) to 9

Open access

Claudia Tulotta and Penelope Ottewell

(as reviewed by Choi et al . 2018 ). Moreover, in the context of tumour relapse after chemotherapy, MRC1 hi , CXCR4 hi , Tie2 hi VEGFA + macrophages have been identified as tumour-supporting M2 macrophages localising in perivascular areas where

Open access

Felicity E B May and Bruce R Westley

Introduction Many of the 1.7 million women diagnosed each year with breast cancer benefit from endocrine therapy ( May 2014 ). Introduced originally for the treatment of breast cancer patients who present or relapse following surgery with

Open access

Haojun Luo, Guanglun Yang, Tenghua Yu, Shujuan Luo, Chengyi Wu, Yan Sun, Manran Liu, and Gang Tu

has been found in ∼40% of the primary breast cancer cases and GPER expression, as an independent unfavorable factor, has been found to correlate with relapse-free survival in patients treated with TAM ( Filardo et al . 2006 , Ignatov et al . 2011

Open access

Martina Gruber, Lavinia Ferrone, Martin Puhr, Frédéric R Santer, Tobias Furlan, Iris E Eder, Natalie Sampson, Georg Schäfer, Florian Handle, and Zoran Culig

was further confirmed in publicly available datasets of mCRPC tissue samples from patients that suffered from relapse after docetaxel treatment ( Kumar et al. 2016 ). Our analysis revealed significantly increased p300 levels (1.5-fold) in patients